Identification
- Summary
Cisatracurium is a skeletal muscle relaxant used to facilitate tracheal intubation, muscle relaxation in surgery, or mechanical ventilation.
- Brand Names
- Nimbex
- Generic Name
- Cisatracurium
- DrugBank Accession Number
- DB00565
- Background
Cisatracurium is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Cisatracurium (DB00565)
- Weight
- Average: 929.16
Monoisotopic: 928.507428607 - Chemical Formula
- C53H72N2O12
- Synonyms
- Cisatracurium cation
Pharmacology
- Indication
For inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Cisatracurium Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium Besylate acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.
- Mechanism of action
Cisatracurium competitively binds to cholinergic receptors in motor end-plate neurons, blocking acetylcholine from accessing the receptors.3 Binding of cisatracurium to cholinergic receptors does not open ion channels, the cell does not depolarize, and the action potential is not transmitted.1
Target Actions Organism ANeuronal acetylcholine receptor subunit alpha-2 antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
The binding of cisatracurium to plasma proteins has not been successfully studied due to its rapid degradation at physiologic pH.
- Metabolism
The degradation of cisatracurium is largely independent of liver metabolism. Results from in vitro experiments suggest that cisatracurium undergoes Hofmann elimination (a pH and temperature-dependent chemical process) to form laudanosine and the monoquaternary acrylate metabolite. The monoquaternary acrylate undergoes hydrolysis by non-specific plasma esterases to form the monoquaternary alcohol metabolite. The monoquaternary alcohol metabolite can also undergo Hofmann elimination but at a much slower rate than cisatracurium. Laudanosine is further metabolized to desmethyl metabolites which are conjugated with glucuronic acid and excreted in the urine.
Hover over products below to view reaction partners
- Route of elimination
Biliary and urinary excretion were the major routes of excretion of radioactivity (totaling >90% of the labeled dose within 7 hours of dosing), of which atracurium represented only a minor fraction.
- Half-life
Elimination half-life of 22 minutes.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Cisatracurium is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of adverse effects can be increased when Cisatracurium is combined with Acetazolamide. Acetophenazine The risk or severity of adverse effects can be increased when Cisatracurium is combined with Acetophenazine. Acetyldigitoxin The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Acetyldigitoxin. Aclidinium Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Agomelatine The risk or severity of adverse effects can be increased when Cisatracurium is combined with Agomelatine. Alfentanil The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alfentanil. Alimemazine The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alimemazine. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Cisatracurium. Almotriptan The risk or severity of adverse effects can be increased when Cisatracurium is combined with Almotriptan. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cisatracurium besylate 80YS8O1MBS 96946-42-8 XXZSQOVSEBAPGS-DONVQRBFSA-L - International/Other Brands
- Nimbex Forte (GlaxoSmithKline) / Nimbium (GlaxoSmithKline)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cisatracurium Besylate Injection Solution 2 mg / mL Intravenous Pfizer Canada Ulc 2015-06-01 2019-03-28 Canada 
Cisatracurium Besylate Injection Solution 2 mg / mL Intravenous Mylan Pharmaceuticals Not applicable Not applicable Canada Cisatracurium Besylate Injection Solution 2 mg / mL Intravenous Accord Healthcare Inc Not applicable Not applicable Canada Cisatracurium Besylate Injection (preservative-free) Solution 2 mg / mL Intravenous Mylan Pharmaceuticals Not applicable Not applicable Canada Cisatracurium Besylate Injection Multi-dose Solution 2 mg / mL Intravenous Fresenius Kabi Not applicable Not applicable Canada Cisatracurium Besylate Injection Single Dose Solution 2 mg / mL Intravenous Fresenius Kabi Not applicable Not applicable Canada Cisatracurium Omega Multidose Solution 2 mg / mL Intravenous Omega Laboratories Ltd 2014-01-20 Not applicable Canada Cisatracurium Omega Single Dose Solution 2 mg / mL Intravenous Omega Laboratories Ltd 2014-01-28 Not applicable Canada Nimbex Injection 10 mg/1mL Intravenous AbbVie Inc. 1995-12-15 Not applicable US 
Nimbex Liquid 2 mg / mL Intravenous Abbvie 1997-04-07 2016-06-07 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Aj-cisatracurium Solution 2 mg / mL Intravenous Agila Jamp Canada Inc Not applicable Not applicable Canada Aj-cisatracurium Solution 2 mg / mL Intravenous Agila Jamp Canada Inc Not applicable Not applicable Canada Cisatracurium Injection, solution 2 mg/1mL Intravenous Fresenius Kabi USA, LLC 2015-02-26 Not applicable US Cisatracurium Injection, solution 10 mg/1mL Intravenous Fresenius Kabi USA, LLC 2015-02-26 Not applicable US Cisatracurium Injection, solution 2 mg/1mL Intravenous Fresenius Kabi USA, LLC 2015-02-26 Not applicable US Cisatracurium Besylate Injection 20 mg/10mL Intravenous Teva Parenteral Medicines, Inc. 2018-09-04 Not applicable US Cisatracurium Besylate Injection 2 mg/1mL Intravenous Piramal Healthcare UK Limited 2021-09-30 Not applicable US Cisatracurium Besylate Injection 2 mg/1mL Intravenous Cadila Healthcare Limited 2020-02-12 Not applicable US Cisatracurium Besylate Injection 2 mg/1mL Intravenous Sandoz Inc 2012-07-16 Not applicable US Cisatracurium Besylate Injection, solution 10 mg/1mL Intravenous Hospira, Inc. 2021-06-01 Not applicable US
Categories
- ATC Codes
- M03AC11 — Cisatracurium
- Drug Categories
- Anticholinergic Agents
- Benzylisoquinolines
- Central Nervous System Depressants
- Heterocyclic Compounds, Fused-Ring
- Isoquinolines
- Muscle Relaxants
- Muscle Relaxants, Peripherally Acting Agents
- Musculo-Skeletal System
- Neuromuscular Agents
- Neuromuscular Blocking Agents
- Neuromuscular Nondepolarizing Blockade
- Neuromuscular-Blocking Agents (Nondepolarizing)
- Nicotinic Antagonists
- Peripheral Nervous System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Isoquinolines and derivatives
- Sub Class
- Benzylisoquinolines
- Direct Parent
- Benzylisoquinolines
- Alternative Parents
- Tetrahydroisoquinolines / Dimethoxybenzenes / Phenoxy compounds / Anisoles / Alkyl aryl ethers / Aralkylamines / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters / Azacyclic compounds show 6 more
- Substituents
- Alkyl aryl ether / Amine / Anisole / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzylisoquinoline / Carbonyl group / Carboxylic acid derivative show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- QX62KLI41N
- CAS number
- 96946-41-7
- InChI Key
- YXSLJKQTIDHPOT-LJCJQEJUSA-N
- InChI
- InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
- IUPAC Name
- (1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-2-(3-{[5-({3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propanoyl}oxy)pentyl]oxy}-3-oxopropyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
- SMILES
- COC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2
References
- General References
- External Links
- Human Metabolome Database
- HMDB0240286
- PubChem Compound
- 62886
- PubChem Substance
- 46506666
- ChemSpider
- 56615
- 319864
- ChEBI
- 140621
- ChEMBL
- CHEMBL1201248
- ZINC
- ZINC000238809664
- Therapeutic Targets Database
- DAP000196
- PharmGKB
- PA164744925
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Cisatracurium_besilate
- MSDS
- Download (25.2 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Neuromuscular Blockade 1 4 Completed Basic Science ARDS, Human / Critically Ill Patients / Neuromuscular Blockade / Paralysis / Respiratory Distress Syndrome, Adult / Respiratory Failure 1 4 Completed Prevention C.Delivery; Surgery (Previous), Gynecological 1 4 Completed Prevention Curarization, Postoperative Residual / Residual Neuromuscular Block 1 4 Completed Prevention Neuromuscular Blockade / Postoperative Complications 1 4 Completed Treatment Acute Respiratory Distress Syndrome (ARDS) 1 4 Recruiting Treatment Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) / Respiratory Distress Syndrome, Pediatric 1 4 Recruiting Treatment Increase in Intracranial Pressure (ICP) / Traumatic Brain Injury (TBI) 1 4 Unknown Status Prevention Anesthetics Adverse Reaction 1 4 Unknown Status Treatment Acute Respiratory Distress Syndrome (ARDS) 1
Pharmacoeconomics
- Manufacturers
- Baxter healthcare corp anesthesia and critical care
- Baxter healthcare corp anesthesia critical care
- Bedford laboratories div ben venue laboratories inc
- Hospira inc
- Marsam pharmaceuticals llc
- Teva parenteral medicines inc
- Abbott laboratories
- Packagers
- Abbott Laboratories Ltd.
- Baxter International Inc.
- Bedford Labs
- Ben Venue Laboratories Inc.
- GlaxoSmithKline Inc.
- Hospira Inc.
- Patheon Inc.
- Teva Pharmaceutical Industries Ltd.
- Dosage Forms
Form Route Strength Injection, solution 2 mg/1ml Injection, solution Intravenous bolus 5 MG/ML Injection, solution 2 MG/ML Injection, solution 5 MG/ML Injection, solution Intravenous bolus 2 MG/ML Injection, solution Injection, solution Intravenous 10 mg/1mL Injection, solution Intravenous 2 mg/1mL Injection, solution Parenteral Injection Intravenous 10 mg/5mL Injection Intravenous 10 mg/1mL Injection Intravenous 2 mg/1mL Injection Intravenous 20 mg/10mL Injection Intravenous 200 mg/20mL Injection, solution Intravenous 10 mg/5mL Injection, solution Intravenous 20 mg/10mL Injection, solution Intravenous 200 mg/20mL Solution Parenteral Solution 2 mg/1ml Solution 2 mg/ml Solution Intravenous 2 mg / mL Injection Intravenous 10 mg Solution Intravenous 10 mg Injection, solution Intravenous 10 mg Injection, solution Intravenous 150 mg Injection, solution Intravenous 20 mg Injection, solution Intravenous 5 mg Injection, solution Intravenous 50 mg Liquid Intravenous 2 mg / mL Liquid Intravenous 10 mg / mL Injection Intravenous Injection, solution Intravenous 150 mg/30ml Injection, solution Intravenous 2 mg/ml Injection, solution Intravenous Solution Intravenous 5 mg Injection, solution 5 mg/1ml - Prices
Unit description Cost Unit Nimbex 10 mg/ml vial 13.8USD ml Nimbex 2 mg/ml vial 2.91USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5453510 No 1995-09-26 2012-09-26 US CA2087104 No 1998-08-18 2011-07-12 Canada
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.32e-05 mg/mL ALOGPS logP 3.41 ALOGPS logP -0.96 ChemAxon logS -7.6 ALOGPS pKa (Strongest Acidic) 19.02 ChemAxon pKa (Strongest Basic) -4.1 ChemAxon Physiological Charge 2 ChemAxon Hydrogen Acceptor Count 10 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 126.44 Å2 ChemAxon Rotatable Bond Count 26 ChemAxon Refractivity 280.68 m3·mol-1 ChemAxon Polarizability 104.19 Å3 ChemAxon Number of Rings 6 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9847 Blood Brain Barrier + 0.9291 Caco-2 permeable - 0.5966 P-glycoprotein substrate Substrate 0.6828 P-glycoprotein inhibitor I Inhibitor 0.7177 P-glycoprotein inhibitor II Inhibitor 0.5808 Renal organic cation transporter Non-inhibitor 0.5871 CYP450 2C9 substrate Non-substrate 0.7994 CYP450 2D6 substrate Non-substrate 0.7779 CYP450 3A4 substrate Substrate 0.6527 CYP450 1A2 substrate Non-inhibitor 0.8244 CYP450 2C9 inhibitor Non-inhibitor 0.7179 CYP450 2D6 inhibitor Non-inhibitor 0.791 CYP450 2C19 inhibitor Non-inhibitor 0.7048 CYP450 3A4 inhibitor Non-inhibitor 0.7338 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8547 Ames test Non AMES toxic 0.544 Carcinogenicity Non-carcinogens 0.5302 Biodegradation Ready biodegradable 0.8169 Rat acute toxicity 2.6124 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6043 hERG inhibition (predictor II) Inhibitor 0.6507
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Drug binding
- Specific Function
- After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
- Gene Name
- CHRNA2
- Uniprot ID
- Q15822
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-2
- Molecular Weight
- 59764.82 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Tuba Z, Maho S, Vizi ES: Synthesis and structure-activity relationships of neuromuscular blocking agents. Curr Med Chem. 2002 Aug;9(16):1507-36. [Article]
Drug created at June 13, 2005 13:24 / Updated at October 07, 2022 09:51